Alfred Scheidegger
Directeur/Membre du Conseil chez DOTTIKON ES HOLDING AG
Postes actifs de Alfred Scheidegger
Sociétés | Poste | Début | Fin |
---|---|---|---|
DOTTIKON ES HOLDING AG | Directeur/Membre du Conseil | 01/07/2011 | - |
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Directeur Général | 07/05/1998 | - |
Fondateur | 07/05/1998 | - | |
Private Equity Investor | 07/05/1998 | - | |
8stogg AG | Directeur/Membre du Conseil | 01/08/2020 | - |
Nextech Venture Principals Ltd.
Nextech Venture Principals Ltd. Financial ConglomeratesFinance Nextech Venture Principals Ltd. provides investment services. The private company is based in Jersey. | Directeur/Membre du Conseil | - | - |
Dottikon Es Management AG | Directeur/Membre du Conseil | - | - |
Dottikon Exclusive Synthesis AG
Dottikon Exclusive Synthesis AG Pharmaceuticals: MajorHealth Technology Dottikon Exclusive Synthesis AG manufactures pharmaceutical ingredients. Its products and services exclusive synthesis, project management, performance chemicals, containment, quality management, recycling and waste treatment, and dottisol. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. | Directeur/Membre du Conseil | - | - |
Nextech III GP AG | Directeur/Membre du Conseil | - | - |
Nextech Holding AG | Président | - | - |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Président | - | - |
░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
Historique de carrière de Alfred Scheidegger
Anciens postes connus de Alfred Scheidegger
Sociétés | Poste | Début | Fin |
---|---|---|---|
░░░░░░ ░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
Formation de Alfred Scheidegger
University of Basel | Doctorate Degree |
Kyoto University | Graduate Degree |
Statistiques
Internationale
Suisse | 14 |
Etats-Unis | 5 |
Allemagne | 3 |
Opérationnelle
Director/Board Member | 13 |
Chairman | 3 |
Chief Executive Officer | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 4 |
Finance | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
DOTTIKON ES HOLDING AG | Process Industries |
TRACON PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 15 |
---|---|
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Finance |
Nextech III GP AG | |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Health Services |
ImVisioN Therapeutics AG
ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Commercial Services |
Nextech Holding AG | |
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Health Technology |
Dottikon Exclusive Synthesis AG
Dottikon Exclusive Synthesis AG Pharmaceuticals: MajorHealth Technology Dottikon Exclusive Synthesis AG manufactures pharmaceutical ingredients. Its products and services exclusive synthesis, project management, performance chemicals, containment, quality management, recycling and waste treatment, and dottisol. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. | Health Technology |
Palyon Medical Corp.
Palyon Medical Corp. Medical SpecialtiesHealth Technology Palyon Medical Corp. develops medical devices for the treatment of chronic pain, spasticity and other neurological diseases. The company was founded by Greg David, David A. Present and Klaus G. Lederer on May 16, 2003 and is headquartered in Santa Clarita, CA. | Health Technology |
Dottikon Es Management AG | |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Swiss Scientific Computing Center
Swiss Scientific Computing Center Miscellaneous Commercial ServicesCommercial Services The Swiss Scientific Computing Center develops and provides supercomputing capabilities to solve important problems in science and society. The private company is based in Manno, Switzerland. | Commercial Services |
Nextech Venture Principals Ltd.
Nextech Venture Principals Ltd. Financial ConglomeratesFinance Nextech Venture Principals Ltd. provides investment services. The private company is based in Jersey. | Finance |
Rising Tide Foundation | Miscellaneous |
8stogg AG | |
Wemedoo AG |
- Bourse
- Insiders
- Alfred Scheidegger
- Expérience